Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted FCF Margin of 25787.5% for Q1 2026, down 4081.66% sequentially from 616.68% in Q4 2025, and down 2550004.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported FCF Margin for 7 years, with the latest figure at 25787.5% in Q1 2026.
- Quarterly FCF Margin fell 2550004.0% year-over-year to 25787.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1409.7% (down 79827.0% YoY) and the FY2025 annual result came in at 625.62%, up 50170.0% from the prior year.
- FCF Margin retreated to 25787.5% in Q1 2026 per IMDX's latest filing, from 616.68% in the prior quarter.
- Over five years, FCF Margin peaked at 261.97% in Q4 2022 and troughed at 25787.5% in Q1 2026.
- A 5-year average of 4423.09% and a median of 1492.99% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin soared 1754396 bps in 2023, then tumbled 2550004 bps in 2026.
- Over 5 years, FCF Margin stood at 261.97% in 2022, then sank by 470 bps to 1492.99% in 2023, then surged by 75 bps to 374.5% in 2024, then slumped by 65 bps to 616.68% in 2025, then slumped by 4082 bps to 25787.5% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 25787.5%, 616.68%, and 2135.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 13.97% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 20.19% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 26.51% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 10.95% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 8.24% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 2.59% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 13.89% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 27.51% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | -25,787.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25,787.50% |
| Dec 31, 2025 | -616.68% |
| Sep 30, 2025 | -2,135.38% |
| Jun 30, 2025 | -1,283.20% |
| Mar 31, 2025 | -287.46% |
| Dec 31, 2024 | -374.50% |
| Sep 30, 2024 | -4,884.35% |
| Jun 30, 2024 | -5,931.73% |
| Mar 31, 2024 | -2,189.77% |
| Dec 31, 2023 | -1,492.99% |
| Sep 30, 2023 | -747.09% |
| Jun 30, 2023 | -1,475.59% |
| Mar 31, 2023 | -2,794.61% |
| Dec 31, 2022 | -261.97% |
| Sep 30, 2022 | -18,291.04% |
| Jun 30, 2022 | -5,217.30% |
| Mar 31, 2022 | -1,421.26% |
| Dec 31, 2021 | -208.02% |
| Sep 30, 2021 | -1,156.20% |
| Jun 30, 2021 | -427.00% |